Pal-Med, Inc.

Pal-Med, Inc. is a specialized provider of medical equipment focused on diabetes management solutions, including Continuous Glucose Monitors and insulin pumps, aimed at improving patient care in the home environment. Pal-Med, Inc. was founded in 1994 and is headquartered in West Columbia, US.

The company is known for providing essential medical equipment for diabetes management. In December 2018, the company was acquired by Solara Medical Supplies, Inc. , a portfolio company of Linden. The financial terms of the acquisition were not disclosed.

Pal-Med, Inc. offers a range of medical equipment that enhances diabetes care at home. The core products include Continuous Glucose Monitors (CGMs) and insulin pumps, which enable patients to monitor their blood glucose and manage insulin delivery effectively. Their services cater to a diverse market, including individuals with diabetes, healthcare providers, and insurance companies across all 47 states in the U.

S. , ensuring timely access to necessary medical supplies delivered to patients' homes. Pal-Med, Inc. generates revenue through direct-to-consumer sales as well as partnerships with healthcare providers and insurance companies.

Patients can order supplies through the myAPP platform or call the service line for assistance. Revenue is derived from insurance reimbursements for prescribed equipment and out-of-pocket payments for non-covered services. Their product offerings, including CGMs and insulin pumps, are central to their revenue model, which builds long-term relationships with both patients and healthcare providers. The company is focused on enhancing its product offerings and expanding its market reach.

While specific upcoming products have not been detailed, their recent acquisition by Solara Medical Supplies, Inc. may lead to potential new product launches. The company aims to improve its service delivery within the existing U. S.

market and potentially extend its reach into new geographic regions in the near future. The most recent acquisition deal on December 7, 2018, will likely facilitate these growth initiatives, although specific funding allocations have not been disclosed.